Hardman Johnston Global Advisors LLC Trims Position in Genmab A/S (NASDAQ:GMAB)

Hardman Johnston Global Advisors LLC lowered its stake in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 5.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 214,472 shares of the company's stock after selling 13,487 shares during the quarter. Hardman Johnston Global Advisors LLC's holdings in Genmab A/S were worth $4,476,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the stock. GAMMA Investing LLC lifted its position in Genmab A/S by 96.6% in the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock valued at $45,000 after acquiring an additional 1,051 shares during the last quarter. Cromwell Holdings LLC grew its holdings in shares of Genmab A/S by 656.8% during the fourth quarter. Cromwell Holdings LLC now owns 2,876 shares of the company's stock worth $60,000 after buying an additional 2,496 shares during the last quarter. R Squared Ltd acquired a new position in Genmab A/S in the 4th quarter valued at about $93,000. Blue Trust Inc. raised its stake in Genmab A/S by 892.0% during the 3rd quarter. Blue Trust Inc. now owns 4,315 shares of the company's stock valued at $108,000 after acquiring an additional 3,880 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC grew its stake in shares of Genmab A/S by 43.6% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 4,653 shares of the company's stock valued at $113,000 after purchasing an additional 1,413 shares during the last quarter. Institutional investors and hedge funds own 7.07% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on GMAB. HC Wainwright reiterated a "buy" rating and issued a $50.00 price objective on shares of Genmab A/S in a research report on Thursday, January 23rd. Sanford C. Bernstein raised shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a report on Friday, December 20th. Leerink Partnrs raised shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a report on Thursday, February 13th. BMO Capital Markets reaffirmed an "outperform" rating and issued a $48.00 price objective (up previously from $46.00) on shares of Genmab A/S in a report on Friday, November 8th. Finally, BNP Paribas upgraded Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Tuesday, February 11th. Four research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $42.17.

Genmab A/S Price Performance

Genmab A/S stock traded up $0.12 during mid-day trading on Thursday, reaching $22.73. The company had a trading volume of 918,544 shares, compared to its average volume of 855,445. The stock's 50-day simple moving average is $20.88 and its 200-day simple moving average is $22.83. Genmab A/S has a 1 year low of $18.64 and a 1 year high of $31.88. The company has a market capitalization of $15.04 billion, a P/E ratio of 13.06, a P/E/G ratio of 2.65 and a beta of 0.96.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, beating the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. On average, equities analysts forecast that Genmab A/S will post 1.45 EPS for the current fiscal year.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.